Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Cancer Discovery|2022Cited by 139
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted TreatmentBeom-Jun Kim, Eric C. Chang, Jonathan T. Lei et al.|Cancer Research Communications|2023Cited by 8
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersEric J. Jaehnig, Meenakshi Anurag, Aranzazu Fernandez-Martinez et al.|Cell Reports Medicine|2025Cited by 3
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0
Supplementary Table from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Matthew J. Ellis, Eric J. Jaehnig et al.|Unknown|2023Cited by 0